Ocrelizumab is a humanized monoclonal antibody currently under clinical investigation and development by the Swiss pharmaceutical company Roche. The therapy is targeted against mature B-lymphocytes with CD20 markers on their surface, giving the drug an immunosuppressive function that might be useful in normalizing the rates of immune attacks made by the host’s immune system against its own myelinated neurons, which form the main pathogenesis of multiple sclerosis (MS).
Read more: http://bit.ly/1JUBLqj
Thanks for your newsletter,do we have any medication for primary progresive ms before we die??
My fiancee has PPMS and I would really love to know how to get him in this study! He is 34 and has 48% of his brain with lesions. His neurologist have told him soon he will “run out of brain” and die of PPMS. His doctor said he has the brain of a 65 year old , but in a 34 year old man
Godspeed & God Bless you all 🙂
JennyO
Dear JennyO,
To known more about ongoing clinical trials on multiple sclerosis, you can register in our Clinical Trial Notification Program (http://multiplesclerosisnewstoday.com/clinical-trial-notification-program/).
Thank you